Table 3.

Summary of subcutaneous ofatumumab pharmacokinetic measures.

	Ofatumumab
	0.3 mg, n = 4	3 mg, n = 6	30 mg, n = 8	60 mg, n = 6	100 mg, n = 3
Cmax^a (ng/ml)	20.0 (NA)^c	18.4 (3.1)^d	827 (93.3)	1519 (865)	3405 (77.2)
Tmax^b (days)	0.497 (0.50–0.50)^c	98.0 (55.96–140.00)^d	4.49 (2.01–7.00)	4.49 (1.00–6.98)	4.02 (4.00–5.02)
AUC (0–∞)^a (ng/day/ml)	NA (NA)^e	NA (NA)^e	7919 (168)^f	38014 (142)^f	50603 (35.5)
Half-life^a (days)	NA (NA)^e	NA (NA)^e	5.20 (63.0)^f	5.64 (80.0)^f	6.83 (45.8)

↵^aGeometric mean (% CVb);
↵^bmedian (range);
↵^cn = 1;
↵^dn = 2;
↵^en = 0 (summary statistics not calculated);
↵^fn = 4. NA: not applicable; Cmax: maximum concentration; AUC: area under the plasma concentration curve; Tmax: maximum ofatumumab plasma concentration.